Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q2 EPS of ($0.25), $0.01 better than the analyst estimate of ($0.26).

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.